This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
by Sundeep Ganoria
ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.
Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Merck (MRK) stood at $81.52, denoting a -2.57% move from the preceding trading day.
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention
by Zacks Equity Research
MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
by Sundeep Ganoria
PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.
The Zacks Analyst Blog Highlights Microsoft, Alibaba Group, Merck, Monarch Cement and Team
by Zacks Equity Research
MSFT, BABA, and MRK headline today's top analyst picks, with AI, global e-commerce, and oncology driving mixed growth stories.
MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?
by Kanishka Das
Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.
Top Analyst Reports for Microsoft, Alibaba & Merck
by Mark Vickery
MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill
by Zacks Equity Research
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
by Zacks Equity Research
Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
by Kinjel Shah
MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
Zacks Investment Ideas feature highlights: QQQ, IWM, SBET, CRCL, COIN, AES, MRK and VRNA
by Zacks Equity Research
QQQ hits its longest streak above the 10-day average in 2025, even as overbought signals and tariff jitters stir caution.
Merck (MRK) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $83.71, moving +2.88% from the previous trading session.
Tariff Turbulence and Overbought Tech Mark Post-Holiday Trading
by Andrew Rocco
While the prevailing bullish sentiment and the market's resilience to tariff news offer encouraging signs, the emergence of short-term caution flags like an overbought Nasdaq and extreme greed sentiment suggest a need for selective and strategic positioning.
Merck Faces Multiple Challenges: Will It Steer Through Successfully?
by Kanishka Das
MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
by Zacks Equity Research
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
GSK's Specialty Medicines Unit on a Strong Footing: Here's Why
by Kinjel Shah
GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck
by Zacks Equity Research
VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
by Kinjel Shah
AZN's oncology sales rise 13% in Q1 2025, driven by key drugs and new approvals. Can this momentum last?
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
by Zacks Equity Research
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?
by Zacks Equity Research
EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
by Zacks Equity Research
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
by Ahan Chakraborty
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $80.93, marking a -1.77% move from the previous day.
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
by Zacks Equity Research
Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE
by Kanishka Das
Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.